Longevity Biotech

Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.

Longevity Biotech, a Philadelphia, PA-based developer of a new class of therapeutics via artificial protein technology. Founded in 2010 by President Mr. Scott Shandler, Longevity Biotech focuses on pharmaceutical preparation. Its hybridtides are targeted biologic-like molecules which are highly-resistant to breakdown by natural digestive enzymes and tunable to very stable molecular structures.